Forsta AP Fonden Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forsta AP Fonden decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 22,100 shares of the biopharmaceutical company’s stock after selling 2,400 shares during the quarter. Forsta AP Fonden’s holdings in Regeneron Pharmaceuticals were worth $15,742,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. raised its holdings in Regeneron Pharmaceuticals by 0.9% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 129,308 shares of the biopharmaceutical company’s stock valued at $92,110,000 after acquiring an additional 1,130 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $435,000. SteelPeak Wealth LLC increased its stake in Regeneron Pharmaceuticals by 154.8% in the fourth quarter. SteelPeak Wealth LLC now owns 2,823 shares of the biopharmaceutical company’s stock valued at $2,011,000 after purchasing an additional 1,715 shares during the last quarter. Tamar Securities LLC lifted its position in Regeneron Pharmaceuticals by 31.7% during the fourth quarter. Tamar Securities LLC now owns 20,401 shares of the biopharmaceutical company’s stock worth $14,532,000 after buying an additional 4,909 shares during the period. Finally, Nilsine Partners LLC boosted its stake in Regeneron Pharmaceuticals by 2.8% in the 4th quarter. Nilsine Partners LLC now owns 1,006 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 27 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.1 %

NASDAQ REGN opened at $687.27 on Thursday. The stock has a market cap of $75.52 billion, a P/E ratio of 17.01, a PEG ratio of 1.59 and a beta of 0.10. The company’s fifty day simple moving average is $724.48 and its 200-day simple moving average is $930.31. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20.

Analysts Set New Price Targets

REGN has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Wells Fargo & Company dropped their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. Royal Bank of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Evercore ISI cut their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.